

## Letter to the Editor

### Methodological and statistical considerations in the assessment of GH-IGF-1 axis dysfunction and linear growth in children with type 1 diabetes mellitus



#### Highlights

1. Long duration T1DM can affect growth of children
2. Pubertal maturation may affect association of GH-IGF1 axis and duration of T1DM, therefore adjustment for pubertal status is compulsory
3. Genetic considerations should be taken in account evaluating growth of children, GH-IGF 1 axis dysfunction and disease duration

**Key words:** Growth hormone, insulin growth factor-1, linear grown, children, type 1 diabetes mellitus, methodology (Heart Vessels Transplant 2026: 10: doi:10.24969/hvt.2026.662)

Dear Editor,

I read the cross-sectional study titled “Association between disease duration, growth hormone (GH)-insulin growth factor (IGF)-1 axis markers, and linear growth in children with type 1 diabetes mellitus (T1DM): a cross-sectional study” by Uvaidillaeva et al. (1) published in Heart, Vessel and Transplantation and found it interesting to learn more about how long duration T1DM can affect children during their growing years. This article is a valuable addition to the field of diabetology. However, I would like to draw attention to some findings in this study that need further discussion. Addressing these points would increase readers’ confidence in conclusions drawn.

The most concerning point is the absence of adjustment for pubertal maturation. IGF-1, like height, the sex steroids and Tanner stages, rises steeply in individuals during puberty, with the timings of the rises tightly synchronized within individuals (2). This manuscript neither reported Tanner staging nor statistically adjusted for it. As the study population ranged from prepubertal childhood to adolescence, the observed associations may have been influenced by variations in pubertal status across the disease duration groups. As a result, the reported inverse

relationship between disease duration and IGF-1 SDS may have been confounded by differences in pubertal status between the disease duration group rather than a true effect of prolonged disease duration.

A second concern relates to the internal inconsistency of the regression outputs reported in IGF-1 SDS row in Table 2 (1). The reported regression coefficient for IGF-1 SDS is  $\beta = -0.245$  with a standard error of 0.076, which yields a t-statistic of approximately  $-3.22$  ( $t = \beta/SE$ ), while the reported t-value is 1.360. It is noteworthy that, the reported 95% confidence interval (0.046 to 0.254) which is entirely positive and thus inconsistent with the negative coefficient ( $\beta = -0.245$ ), as a confidence interval for a negative coefficient should statistically be expected to include negative values. Taken together, these disparities indicate that these values may have been incorrectly reported or calculated. Clarification is necessary before the regression results can be interpreted with confidence.

Third, the negative regression coefficient raises a biological interpretative difficulty, as it points towards the inverse relation between IGF-1 SDS and height SDS after adjustment.

**Address for Correspondence:** Umair Moin ud din, Khawaja Muhammad Safdar Medical College, 51310, Sialkot, Pakistan

**Email:** umairmoinuddin6@gmail.com **Mobile:** +923278769811

**ORCID:** 0009-0003-8360-0852

**Citation:** Moin ud din U. Methodological and statistical considerations in the assessment of GH-IGF-1 axis dysfunction and linear growth in children with type 1 diabetes mellitus. Heart Vessels Transplant 2026: 10: doi:10.24969/hvt.2026.662

**Received:** 29.06.2026 **Accepted:** 30.06.2026

**Copyright ©2026 Heart, Vessels and Transplantation**

This is an open access article CC-BY-NC-ND 4.0 license (<http://hvt-journal.com/pages/aims-scope>)

This finding counters the well-established claim that GH-IGF-I axis is a key endocrine mechanism regulating linear growth in children (3). In Table 1 both IGF-1 SDS and height SDS decline with increasing disease duration of T1DM (height SDS: from 0.08 to -0.34 to -1.01 and IGF-1 SDS: from -1.62 to -1.35 to -1.90). This suggests that both of these variables are influenced by disease duration alone rather than having an inverse relationship. While, Table 2 showed a conditional association between IGF-1 SDS and height SDS, which is quite opposite to the unadjusted descriptive trends in Table 1.

Finally, genetics plays a major role in determining human stature. Studies report that resemblances in height between relatives suggest that 80% of height variation is under genetic control with the rest controlled by environmental factors such as diet and disease exposure(4). Without adjusting for genetic determinants of height, the reported findings may have been affected by residual confounding. As a result, the observed variation in height may be partially influenced by genetic factors and not the effect of T1DM disease duration alone.

Umair Moin ud din\*

Khawaja Muhammad Safdar Medical College, Sialkot,  
Pakistan

**Peer-review:** Internal

**Conflict of interest:** None to declare

**Authorship:** U.M. The author solely conceived the idea, drafted the manuscript and critically reviewed and approved the final version

**Acknowledgements and Funding:** None to declare

**Statement on A.I.-assisted technologies use:** Authors did not use A.I. in preparation of manuscript

**Data and material availability:** Not available

## References

- 1.Uvaidillaeva F, Tukhvatshin R, Kniazeva V, Omurkulova B. Association between disease duration, GH-IGF-1 axis markers, and linear growth in children with type 1 diabetes mellitus: a cross-sectional study. *Heart Vessels Transplant* 2026; 10: doi:10.24969/hvt.2026.642
- 2.Cole TJ, Ahmed ML, Preece MA, Hindmarsh P, Dunger DB. The relationship between Insulin-like Growth Factor 1, sex steroids and timing of the pubertal growth spurt. *Clin Endocrinol (Oxf)* 2015; 82: 862–9. doi:10.1111/cen.12682
- 3.Blum WF, Alherbish A, Alsagheir A, El Awwa A, Kaplan W, Koledova E, et al. The growth hormone–insulin-like growth factor-I axis in the diagnosis and treatment of growth disorders. *Endocr Connect* 2018; 7: R212–22. doi:10.1530/EC-18-0099
- 4.McEvoy BP, Visscher PM. Genetics of human height. *Econ Hum Biol* 2009; 7: 294–306. doi:10.1016/j.ehb.2009.09.005